This series consists of three case discussions on practical challenges in the management of patients with heart failure. The discussions are moderated by prof. Mark Petrie, Glasgow, UK.
RAAS inhibitors can cause hyperkalemia in HF patients leading to RAASi downtitration or discontinuation. Novel potassium binders may improve management of HF patients by continuation of RAASi.
HF biomarkers and CV risk factors were strongly associated with incident HF without any sex-related differences among women and men.
In the AFFIRM-AHF trial, the primary endpoint was just missed. The trial evaluated the effect of intravenous ferric carboxymaltose compared to placebo on HF hospitalizations and CV death in acute HF patients with iron deficiency.
Prof. Ponikowski discusses the importance of optimization of RAASi treatment through long-term potassium control in HF patients with hyperkalemia.
A subanalysis of the PIONEER-HF trial showed that sacubitril/valsartan lowered NT-proBNP and clinical outcomes compared to enalapril, irrespective of HF history or ACEi/ARB treatment status.
In a subanalysis of the DAPA-HF study, dapagliflozin improved CV outcomes in HFrEF patients when compared to placebo, irrespective of baseline SBP.
Prof. Lam discusses important effects of comorbidities in HF patients and how these comorbidities may affect the use of treatments for HF.
Hyperkalemia drives suboptimal use of RAASi therapy, which is associated with increased CV risk in HF patients. Prof. Zannad presents trial results with the new potassium binders ZS-9 and patiromer.
This substudy of the PARAGON-HF trial demonstrated that in HFpEF patients, sacubitril/valsartan reduced the risk of a composite of renal outcomes and attenuated decline in kidney function compared to valsartan alone.
Two cardiologists, one in an ambulatory setting and one in a hospital setting, discuss the treatment of a severe heart failure patient following an MI over the course of two years.
A large pupil area in patients admitted with acute HF was significantly associated with a lower all cause mortality and hospital readmission due to HF compared to a small pupil area.